Citadel Advisors »

Enliven Therapeutics shares owned by Citadel Advisors

Quarter-by-quarter ownership of Enliven Therapeutics (ELVN) shares owned by Citadel Advisors from 13F filings

Historical chart of Citadel Advisors investment in Enliven Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Enliven Therapeutics held by Citadel Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Enliven Therapeutics by Citadel Advisors

Quarter filed Position value Share count Share price at filing
2023-12-31 $33M 2.4M 13.84
2023-09-30 $32M 2.4M 13.66
2023-06-30 $47M 2.3M 20.41
2023-03-31 $50M 2.3M 21.90

More positions owned by Citadel Advisors

Spdr S&p 500 Etf Tr Tr Unit Call Option (SPY)
Invesco Qqq Tr Unit Ser 1 Call Option (QQQ)
Tesla Motors Call Option (TSLA)
NVIDIA Corporation Call Option (NVDA)
Ishares Tr Russell 2000 Etf Call Option (IWM)
Microsoft Corporation Call Option (MSFT)
Meta Platforms Cl A Call Option (META)
Apple Call Option (AAPL)
Amazon Call Option (AMZN)
Ishares Tr Iboxx Hi Yd Etf Call Option (HYG)
Alphabet Cap Stk Cl A Call Option (GOOGL)
Advanced Micro Devices Call Option (AMD)
Netflix Call Option (NFLX)
Alphabet Cap Stk Cl C Call Option (GOOG)
Booking Holdings Call Option (BKNG)

View all positions for Citadel Advisors

Top funds holding Enliven Therapeutics

OrbiMed Advisors
5AM Venture Management
VR Adviser
Commodore Capital
Citadel Advisors
Fairmount Funds Management
RA Capital Management
Vanguard Group
Boxer Capital
Henderson Group
Logos Global Management
Charles Schwab Investment Management
Bank of New York Mellon
BML Capital Management
Barclays

View all funds holding Enliven Therapeutics